1-6 of 6
Nizar Abdel-Samad
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Clinical Trials & Observations
Mitchell R. Smith, Opeyemi A. Jegede, Peter Martin, Brian G. Till, Samir S. Parekh, David T. Yang, Eric D. Hsi, Thomas Witzig, Sandeep Dave, David Scott, Curtis Hanson, Lale Kostakoglu Shields, Nizar Abdel-Samad, Carla Casulo, Nancy L. Bartlett, Paolo F. Caimi, Tareq Al Baghdadi, Kristie A. Blum, Mark D. Romer, David J. Inwards, Rachel E. Lerner, Lynne I. Wagner, Richard F. Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl
Journal: Blood
Blood (2024) 144 (10): 1083–1092.
https://doi.org/10.1182/blood.2024023962
Published: 2024
Includes: Supplemental data
Journal Articles

Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP

Douglas A. Stewart, Lois E. Shepherd, Jill J. Dudebout, Jean-François Larouche, Neil Chua, Tara Baetz, Michael Crump, Mona Shafey, Nizar Abdel-Samad, Sue Robinson, Isabelle Fleury, Deborah Marcellus, Pamela Skrabek, Jesse Kelly, Annette E. Hay, Bingshu Chen, John Kuruvilla
Journal: Blood
Blood (2022) 140 (Supplement 1): 3734–3736.
https://doi.org/10.1182/blood-2022-163706
Published: 2022
Journal Articles

Pembrolizumab Added to First-Line Cyclophosphamide, Bortezomib and Dexamethasone in Newly Diagnosed Transplant Non-Eligible Myeloma Patients: A Phase 2A Open Label, Multi Centre Study

Rami Kotb, Engin Gul, Nizar Abdel-Samad, Ibraheem Othman, Michel Pavic, Donna E. Reece
Journal: Blood
Blood (2021) 138 (Supplement 1): 4768.
https://doi.org/10.1182/blood-2021-153897
Published: 2021
Journal Articles

Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada

Versha Banerji, Nizar Abdel-Samad, Andrew Aw, Sarah-Jane Bull, Pierre-André Fournier, Nathalie Johnson, Nicole B. Laferriere, Paola Lembo, Christina H Pelizon, Anthea Peters, Carolyn Owen
Journal: Blood
Blood (2021) 138 (Supplement 1): 3744.
https://doi.org/10.1182/blood-2021-146001
Published: 2021
Journal Articles

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Matthew C. Cheung, MDMSc, Nicole Mittmann, PhD, Carolyn Owen, MDFRCPC, Nizar Abdel-Samad, MD, Graeme Fraser, Selay Lam, MDBSc,FRCPC, Michael Crump, MD, Catherine Sperlich, Richard van der Jagt, Stephen Couban, MDBSc, Jennifer A. Woyach, MD, Amy S. Ruppert, PhD, Allison M Booth, Sumithra J Mandrekar, PhD, Gail T. McDonald, Lois E. Shepherd, Anca Prica, MD, Hope Yen, Bingshu E. Chen, Annette E. Hay
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–30.
https://doi.org/10.1182/blood-2020-136692
Published: 2020
Journal Articles

Granulocyte Colony-Stimulating Factor (GCSF) Use with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone +/- Rituximab (CHOP±R) Treatment for Aggressive Non-Hodgkin's Lymphoma (aNHL)

Tom Kouroukis, MD, Winson Y. Cheung, Nizar Abdel-Samad, Sandeep Sehdev, Melanie Poulin-Costello, Brad Gillesby, Ewan J.D. Robson
Journal: Blood
Blood (2016) 128 (22): 3038.
https://doi.org/10.1182/blood.V128.22.3038.3038
Published: 2016